Leading radiologists to highlight
clinical examples demonstrating power of iCAD’s complete suite of ProFound AI
Breast Health Solutions


NASHUA, N.H. – June 29, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that
radiologists will highlight clinical examples demonstrating the power of ProFound AI® Risk in an upcoming webinar titled “ProFound AI Risk in
the Real-World” on Monday, July 18 at 9 am PT/12
noon ET/6 pm CEST.
Visit this link to register.


The latest installment of the
Company’s recently launched “ProFound Insights, ProFound Impact” webinar
series, the live event will be moderated by iCAD’s Product
Director of AI Solutions, Andjela Azabagic, and will feature the following
distinguished experts:

  • Axel Gräwingholt, MD, Radiologie am Theater,
    Paderborn, Germany
  • Mark Traill, MD, University of Michigan
    Health-West, Wyoming, Michigan

The event
follows iCAD’s recent “
Risk Assessment Reimagined” webinar, where
these experts previewed case studies and joined in a roundtable discussion with
a distinguished researcher from the Karolinska Institutet who assisted in the
development of the ProFound AI Risk algorithm.


“We are
delighted to have Dr. Traill and Dr. Gräwingholt return to our virtual stage
for this encore event and clinical case study review,” said Ms. Azabagic, who
also moderated the previous event. “The clinical cases already shared were compelling
examples of the power of iCAD’s technology, and we look forward to taking a
deeper dive as they share additional, real-world cases demonstrating how the
ProFound AI® Breast Health Suite can help radiologists
personalize women’s breast cancer
screening based on their short-term risk and find cancers earlier.”


Hear from the event’s featured experts:

“iCAD has been the leader in this
space for a long time, and their technologies are the real deal. With iCAD’s
suite of ProFound AI Breast Health Solutions, my cancer detection rate has
increased, I am more productive than ever, and my stress level has decreased.
This technology offers a real triple threat that is clinically proven to
improve radiologists’ performance and enhance patient care.”


Traill, MD, University of Michigan Health-West, Wyoming, MI


“We have found iCAD’s ProFound AI
Breast Health Solutions have offered significant value at my facility, as the
technology has significantly improved our efficiency and cancer detection rates.
These solutions are powerful tools that offer radiologists more insight into a
woman’s individual case, improve confidence and help in clinical decision


Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany


iCAD’s “ProFound Insights, ProFound Impact” webinar series launched
earlier this year, featuring distinguished clinical, IT and administrative
experts, customer success stories and impactful case studies. P
revious event recordings are available
on the Company’s website, www.icadmed.com.


About iCAD, Inc.

Headquartered in
Nashua, NH, iCAD® is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit


Forward-Looking Statements

Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements about the expected benefits
of ProFound AI®, the benefits of the Company’s products, and future prospects
for the Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance, or achievements of the
Company to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
business and strategic objectives, the willingness of patients to undergo
mammography screening in light of risks of potential exposure to Covid-19,
whether mammography screening will be treated as an essential procedure, whether
ProFound AI will improve reading efficiency, improve specificity and
sensitivity, reduce false positives and otherwise prove to be more beneficial
for patients and clinicians, the impact of supply and manufacturing constraints
or difficulties on our ability to fulfill our orders, uncertainty of future
sales levels, to defend itself in litigation matters, protection of patents and
other proprietary rights, product market acceptance, possible technological
obsolescence of products, increased competition, government regulation, changes
in Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.




Burns, iCAD 






Investor Relations